OUR STORY
Canvas 1839 is a community brought together by the restorative power of Hemp Cannabidiol (CBD). We believe deeply in the ritual of wellness. Every day, we strive to take care of ourselves, each other, and the world around us.
Through collaborations with Austin originals, we highlight new creative perspectives on modern health and wellness, harnessing nature’s original medicine with modern recipes.
Canvas 1839 creates the most bioavailable product on the market today. Our revolutionary molecular Uptake Ph.D TM ensures that all our products are consistently faster absorbing and faster acting than any other brand. We help you cultivate balance along multiple dimensions in the mind and body, be it better sleep, improved focus, or eased muscles and joints, so that you can get back to life.
Our products are made with 100% ultra-potent, pharmaceutical-grade CBD and are never psychoactive. Canvas 1839 products contain very low and legal concentrations of THC (0.3% or less.). Our scientific research and development is led by Chief Science Officer and Stanford grad Dr. Kyle Hammerick, whose pioneering work in Nanoscale Biology has myriad applications in CBD.
Canvas 1839. Original Medicine.
Through collaborations with Austin originals, we highlight new creative perspectives on modern health and wellness, harnessing nature’s original medicine with modern recipes.
Canvas 1839 creates the most bioavailable product on the market today. Our revolutionary molecular Uptake Ph.D TM ensures that all our products are consistently faster absorbing and faster acting than any other brand. We help you cultivate balance along multiple dimensions in the mind and body, be it better sleep, improved focus, or eased muscles and joints, so that you can get back to life.
Our products are made with 100% ultra-potent, pharmaceutical-grade CBD and are never psychoactive. Canvas 1839 products contain very low and legal concentrations of THC (0.3% or less.). Our scientific research and development is led by Chief Science Officer and Stanford grad Dr. Kyle Hammerick, whose pioneering work in Nanoscale Biology has myriad applications in CBD.
Canvas 1839. Original Medicine.
FEATURED NEWS
Austin Chronicle
CBD Companies Find Practical Uses for Marijuana Compounds
Jess Cape – June 7th, 2019
OUR TEAM
Jason Luce
CEO & Co-Founder, Canvas 1839 Group
Jason Luce is CEO and co-founder of Canvas 1839 Group, a company focused on creating optimized drug delivery technologies in the cannabis space. Luce co-founded Canvas 1839 with a mission to bring the restorative power of hemp to people everywhere through superior products based on trusted science. Under Luce’s leadership, Canvas 1839 Group has launched a CBD-only line (Canvas CBD) sold nationally via ecommerce and in-store retailers, and has spearheaded the effort to get Canvas 1839 Group’s dispensary channel cannabis business, Escape Artists, into more than 450 dispensaries in Colorado. Luce is continuing to drive the Escape Artists business towards multi-state expansion and is building retail and DTC efforts on the Canvas CBD side.
Born and raised in Austin, Texas, Luce’s career began in law in New York City and London, working with some of the world’s top law firms. Realizing that his strengths and passions leaned more towards numbers and financial modeling, he transitioned into investment banking at Lehman Brothers and Morgan Stanley.
In 2007, Luce took the opportunity to move back to Texas, where he joined Rackspace as Vice President of Finance before co-founding his own cybersecurity start-up, ScaleFT. At ScaleFT, he served as CEO, overseeing the company’s rapid growth until its acquisition by Okta in 2017.
Luce has three sons, Julian, Quincy, and Wesley.
Laura Komkov
Co-Founder, Canvas 1839 Group
Laura Komkov is a co-founder of Canvas 1839, a company focused on creating optimized drug delivery technologies in the cannabis space, where she manages product and customer experience. Responsible for overseeing the development of Canvas CBD-only products, packaging, and educational materials, she has a strong understanding of customer needs and desires. In addition to overseeing product, she is involved hands-on in all of the day-to-day aspects of the business, regularly attending events as a representative and speaker, answering customer questions, writing content, and deeply researching cannabis. Komkov’s motivation to co-found Canvas 1839 Group stemmed from autoimmune and genetic problems that she’s experienced since age 12 -- she has a deep knowledge of both traditional and non-traditional healing methods, learned from personal experience as a “medical unicorn.”
Komkov joined the Canvas 1839 team from Seton Foundations, a part of Ascension Healthcare, where she served as Director of Strategic Initiatives with a specific emphasis on improving Seton’s digital presence, content, and online fundraising capabilities. Prior to Seton, Komkov spent time at a first-party data startup and at Hill+Knowlton Strategies, where she worked with clients in public affairs, energy, food and beverage, retail, education, and healthcare.
Komkov is from Austin and attended The University of Texas at Austin where she majored in theater and dance, and art history. In her spare time, she enjoys acting (particularly comedy/improv), watching and participating in a variety of sports, and playing with her dog, Ted (who might actually be a muppet).
Kyle Hammerick
CTO of Canvas 1839 Group & PhD
Kyle Hammerick is chief technology officer (CTO) of Canvas 1839 Group, a company focused on creating optimized drug delivery technologies in the cannabis space. Hammerick has more than 15 years of experience in the biotech and pharmaceutical industries with a special emphasis on therapies and technologies in healthcare for early-stage companies. He has spent the past two and a half years developing novel delivery mechanisms for cannabinoids, including transmucosal oral technologies and transdermal topical delivery strategies. Hammerick has also put considerable effort into bringing applicable quality control and regulatory oversight from pharmaceutical and medical device industries to the cannabis space.
Prior to his involvement in cannabis therapeutic development, Hammerick oversaw the R&D program and manufacturing of products for clinical trials at startup pharmaceutical company BioInspire Technologies, and led the 510(k) approval for BioInspire’s sinus device. In academia, Hammerick worked on several technologies for programmed drug delivery, which were spun out to form a startup ophthalmic company, InSitu Therapeutics. Hammerick has a BS from Rice University and a MS and PhD from Stanford University.
PRESS RELEASES
Living a Lifestyle of Wellness with Canvas 1839 CBD
September 1st, 2019
